Why the study?
Anticoagulant therapy for venous thromboembolism has shifted from warfarin to direct oral anticoagulants, and new evidence has emerged since the previous guideline.
The 2025 JCS guidelines provide updated recommendations for VTE management, reflecting the transition to DOACs and incorporating new evidence on COVID-19-associated thrombosis.
Answers are grounded in this paper and cite their sources.
Updated 2025 Japanese VTE guidelines favor DOACs and add COVID-19 guidance; leaves open unresolved questions for future trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yugo YAMASHITA (2025) conducted a review in Venous thromboembolism. 2025 JCS Guidelines for VTE was evaluated. The 2025 Japanese Circulation Society guidelines for venous thromboembolism updated treatment recommendations to include outpatient management for low-risk pulmonary embolism and DOAC-based strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: